Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-17
    E.g., 2018-11-17

Articles

173760 items
10:00 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

SVB acquiring Leerink amid record year for IPOs

With IPOs continuing at a torrid pace, SVB Financial Group (NASDAQ:SIVB), the parent company of high-tech commercial lender Silicon Valley Bank, announced on Oct. 13 that it will acquire Leerink Partners for $280 million. Leerink, a...
9:57 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

BioCardia's CardiAMP non-significantly improves 6MWD in roll-in cohort of Phase III for heart failure

BioCardia Inc. (OTCQX:BCDA) reported data from the 10-patient roll-in cohort of the Phase III CardiAMP Heart Failure trial to treat heart failure following a heart attack showing that CardiAMP non-significantly improved mean 6-minute walk distance...
9:55 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Regulatory

Gelesis submits device application to FDA for hydrogel weight loss product

Gelesis Inc. (Boston, Mass.) said it submitted a medical device marketing application to FDA over the summer for weight loss product Gelesis100 as an adjunct to a hypocaloric diet and moderate physical activity. The company...
9:55 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Daiichi, GSK to dissolve vaccines JV

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to dissolve their JV, Japan Vaccine Co. Ltd. In a statement, Daiichi said, “in consideration of changes in the Japan Vaccine business situation, both...
9:44 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

AbbVie strengthens early stage neurology focus with Mission deal

Mission Therapeutics Ltd. (Cambridge, U.K.) and AbbVie Inc. (NYSE:ABBV) partnered to develop deubiquitinase inhibitors for Alzheimer's and Parkinson's diseases. The deal is the second in as many weeks for AbbVie for early stage neurology candidates. Deubiquitinases,...
9:43 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Synthrox proposes $100M IPO ahead of synthetic IL-2 clinical testing

Synthetic biology company Synthorx Inc. (La Jolla, Calif.) proposed to raise $100 million in a NASDAQ IPO, according to an SEC filing from Nov. 13. Synthorx is using synthetic biology to develop a pipeline of Synthorin...
9:40 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Helperby, UCLA to explore antibiotic combos

Helperby Therapeutics Ltd. (London, U.K.) partnered with University of California Los Angeles (Los Angeles, Calif.) to develop undisclosed combinations of antibiotics. The partners will target antimicrobial resistant bacteria and under the deal will share data and...
9:38 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

Samsung BioLogics trading suspended after accounting violations

Korea’s Securities and Futures Commission (SFC) temporarily suspended trading of Samsung BioLogics Co. Ltd. (KSE:207940) for violating accounting rules. The commission also recommended an W8 billion ($7 million) fine and the dismissal of Samsung BioLogics'...
9:38 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

bioMérieux grows China footprint with majority stake in Hybiome

Increasing its presence in China and the immunoassay market, France’s bioMérieux S.A. (Euronext:BIM) acquired a majority stake in fellow diagnostics company Suzhou Hybiome Biomedical Engineering Co. Ltd. (Suzhou, China). bioMérieux said it acquired 54% of...
9:37 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Regulatory

Pfizer launches U.S.’s first biosimilar epoetin

Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen and Johnson...

Pages